Long-term efficacy of Gilenya reinforced by new analysis
Long-term efficacy of Gilenya reinforced by new analysis
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1618 Views
-
Last post by NHE
-
- 1 Replies
- 1849 Views
-
Last post by frodo
-
- 0 Replies
- 849 Views
-
Last post by frodo
-
- 0 Replies
- 1307 Views
-
Last post by frodo
-
- 0 Replies
- 9989 Views
-
Last post by NHE
-
- 0 Replies
- 967 Views
-
Last post by frodo
-
- 41 Replies
- 5486 Views
-
Last post by jimmylegs
-
- 5 Replies
- 13392 Views
-
Last post by gibbledygook